Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat with or without decitabine before donor lymphocyte infusion after allogeneic stem cell transplantation in poor-risk AML/RAEB
NL-OMON50408Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of panobinostat and decitabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by HOVON. Primary endpoints: Feasibility of protocol treatment in Part I, Feasibility of protocol treatment in Part II and 1 more. Started Jan 2014; status: active, not recruiting.
02
Drugs
panobinostatdecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON50408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50408.